Clinical Trial Update: Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating DEFENCATH for reducing central-line associated bloodstream infections in adults on total parenteral nutrition via a central …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Line Associated Blood Stream Infections

Drugs mentioned

• DEFENCATH (taurolidine and heparin)

Snippet

Sponsor: CorMedix | Conditions: Central Line Associated Blood Stream Infections (CLABSI) | Phase 3 | Status: RECRUITING